US 10,722,559 B2 · Mannose-6-phosphate bearing peptides fused to lysosomal enzymes

Abstract

A targeted therapeutic including a lysosomal enzyme and a lysosomal targeting moiety that is a peptide containing at least one N-linked glycosylation site. Methods of producing the targeted therapeutic may include nucleotide acids encoding the same and host cells co-expressing GNPT. Pharmaceutical compositions comprising the targeted therapeutic and methods of using the same to treat a lysosomal storage disease.

Claims11

Dependent claims

A nucleic acid encoding a targeted therapeutic fusion protein comprising:

a lysosomal enzyme, and
a lysosomal targeting moiety,
wherein the lysosomal targeting moiety is a prosaposin peptide comprising an amino acid sequence of SEQ ID NO:
4, containing at least one N-linked glycosylation site, and
wherein the fusion protein, once administered in vivo, results in reduced lysosomal storage.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/503,223Filed 11 Aug 2015 · us provisional application

Priority

11 Aug 2014

Published

US 2017/0232076 A117 Aug 2017

Granted

28 Jul 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 38/47
Hydrolases: acting on glycosyl compounds , e.g. cellulases, lactases
A61K 38/1709
From vertebrates: from mammals
A61K 38/204
Interleukins [IL]: il-6
A61K 38/30
Hormones: insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Mannose-6-phosphate bearing peptides fused to lysosomal enzymes

Life of this patent

Mannose-6-phosphate bearing peptides fused to lysosomal enzymes

Life of this patent

Abstract

Claims11